Any restrictions to limit access to medicinal cannabis will adversely impact patients and simply drive users to the illicit market, the industry has warned, as it hit back at calls to remove the medicine from the Special Access Scheme (SAS).
In a joint letter to the Therapeutic Goods Administration (TGA), Queensland representatives from the Australian Medical Association (AMA), the Royal Australian and New Zealand College of Psychiatrists (RANZCP) and the Pharmacy Guild of Australia urged the regulator to address what they claimed were “inadequate controls” on medicinal cannabis.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and
international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
